Malaysia Liver Cancer Therapeutics Market Report 2022 to 2030

Malaysia Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Malaysia Liver Cancer Therapeutics market will reach a value of $17.5 Mn from $4.71 Mn in 2022, growing at a CAGR of 17.8% during 2022-2030. Liver Cancer Therapeutics in Malaysia is dominated by a few domestic pharmaceutical companies such as Pharmaniaga, Pantai Hospital and National Cancer Institute. The Liver Cancer Therapeutics market in Malaysia is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Malaysia Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10MYPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Malaysia AUTHOR: Dr. Vishwa Modhia

Buy Now

Malaysia Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Malaysia Liver Cancer Therapeutics market will reach a value of $17.5 Mn from $4.71 Mn in 2022, growing at a CAGR of 17.8% during 2022-2030.

Malaysia, being an upper-middle-income, developing country, is a federation of 13 states and three federal territories in Southeast Asia. According to the most recent WHO data, 1,984 people died from liver cancer in Malaysia in 2020, accounting for 1.18 % of all deaths. Malaysia ranks 57th in the world with an age-adjusted death rate of 6.96 per 100,000 inhabitants. In Malaysia, the five-year survival rate for liver cancer is roughly 11 %. This is due in part to the fact that liver cancer is frequently not detected until it is advanced.

After breast and lung cancer, liver cancer is the third most frequent cancer in Malaysia. In Malaysia, it is anticipated that there will be 6,118 new cases of liver cancer in 2020. Malaysian pharmaceutical businesses, such as Pharmaniaga and Hovid, play an essential role in the development and distribution of liver cancer treatments. Malaysia's government spent 4.1 % of its GDP on healthcare in 2020.

Malaysia Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Malaysia's government has launched a number of steps to improve the prevention and treatment of liver cancer in the country, including a nationwide hepatitis B vaccination programme and the construction of cancer screening programmes. Liver cancer is a major problem in Malaysia, with the disease's prevalence rising in recent years. This is due in part to the country's high prevalence of hepatitis B and C infections, both of which are substantial risk factors for liver cancer. These aspects could boost Malaysia's Liver Cancer Therapeutics market.

Market Restraints

Patients with liver cancer may encounter stigma and prejudice in some situations due to the disease's link with drunkenness or other socially unacceptable habits in Malaysia. Some people may be discouraged from seeking medical treatment or reporting their illness to others as a result of this. Malaysia's price competitiveness may suffer as a result of increased labour costs, stifling corporate activities in the country. These factors may deter new entrants into the Malaysia Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

University Malaya Medical Centre (UMMC): UMMC is a public hospital in Kuala Lumpur that offers liver cancer treatment services. The hospital has a dedicated Liver Cancer Clinic that provides a multidisciplinary approach to treatment, including surgery, chemotherapy, and radiotherapy
National Cancer Institute (NCI): NCI is a public hospital in Putrajaya that specializes in cancer treatment and research
Gleneagles Kuala Lumpur: Gleneagles Kuala Lumpur is a private hospital in Kuala Lumpur that provides liver cancer treatment services
Pantai Hospital Kuala Lumpur: Pantai Hospital Kuala Lumpur is a private hospital in Kuala Lumpur that offers liver cancer treatment services. The hospital has a dedicated Liver Centre that provides a comprehensive approach to treatment, including surgery, chemotherapy, and radiotherapy
Pharmaniaga: Pharmaniaga is a Malaysian pharmaceutical company that develops and distributes liver cancer drugs. The company focuses on developing and manufacturing generic drugs for cancer treatment, including liver cancer

Recent Notable updates

October 2022: Pharmaniaga Berhad (Pharmaniaga) signed a Memorandum of Understanding (MoU) with JDMAS Commerce Sdn Bhd (JDMAS) to commercialise Pharmaniaga's over-the-counter (OTC) and, later, pharmaceutical products in China via JD. Com with JDMAS's support. JDMAS, the official partner of JD. Com, China's largest and the world's third-largest online retailer, was established and recognised by various agencies including Malaysia Trade Development Corporation (MATRADE), the Ministry of International Trade and Industry (MITI), and Malaysia China Business Council (MCBC) (MDEC).

Healthcare Policies and Reimbursement Scenarios

In Malaysia, the regulation and reimbursement of liver cancer therapeutics are governed by the Malaysian National Pharmaceutical Regulatory Agency (NPRA) and the Ministry of Health (MOH). In Malaysia, the MOH manages the country's healthcare system and is responsible for determining which healthcare services and treatments are covered by the public healthcare system. Liver cancer therapeutics are typically covered under the country's National Health Insurance Scheme, which provides subsidized healthcare services to all Malaysian citizens and permanent residents.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.